Research programme: cancer therapeutics - Eternity Bioscience

Drug Profile

Research programme: cancer therapeutics - Eternity Bioscience

Alternative Names: Anaplastic lymphoma kinase inhibitors - Eternity Bioscience; BRAF inhibitors - Eternity Bioscience; BTK inhibitors - Eternity Bioscience; EBI 1041; EBI 2554; EBI-1051; EBI-1266; EBI-1367; EBI-907; EBI-945; MEK1 inhibitors - Eternity Bioscience; PARP-1/2 inhibitors - Eternity Bioscience

Latest Information Update: 23 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eternity Bioscience
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; EZH2 enzyme inhibitors; MAP kinase kinase 1 inhibitors; Poly(ADP-ribose) polymerase inhibitors; Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Breast cancer; Cancer; Ovarian cancer

Most Recent Events

  • 23 Sep 2016 Cancer therapeutics - Eternity Bioscience are available for licensing worldwide as of September 2016 https://sites.google.com/a/eternitybioscience.com/eternity-bioscience-inc/financials-products
  • 04 Nov 2013 Cancer therapeutics - Eternity Bioscience are available for licensing worldwide (excluding China) as of 04 Nov 2013. http://www.eternitybioscience.com/
  • 04 Nov 2013 Preclinical trials in Breast cancer (BCRA1/2 deficient) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top